Previous 10 | Next 10 |
2024-01-22 14:00:02 ET William Blair analyst issues OUTPERFORM recommendation for IONS on January 22, 2024 02:35PM ET. The previous analyst recommendation was Outperform. IONS was trading at $51.455 at issue of the analyst recommendation. The overall analyst consensus : ...
2024-01-22 08:00:31 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript Ionis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation FDA approv...
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema PR Newswire Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients tr...
2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...
2024-01-18 12:45:02 ET Piper Sandler analyst issues BUY recommendation for IONS on January 18, 2024 01:00PM ET. The previous analyst recommendation was Buy. IONS was trading at $50.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...
2024-01-16 11:49:56 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value Citi’s 30 stocks for its 2024 top themes Top overweight stocks with high growth and low volume - MS Seeking Alpha’s Quant Rating...
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort Enrollment for both ulixacaltamide Phase 3 Studies in the Essential3...
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases PR Newswire – Numerous value-driving commercial, regulatory and pipeline milestones anticipated – ...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2024-01-02 16:14:13 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript Ionis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation FDA approv...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...